NHS England statement on Alzheimer’s treatment lecanemab: Thursday 22 August 2024
In response to the MHRA and NICE decisions on lecanemab, Professor Sir Stephen Powis, NHS National Medical Director, said: “The NHS now awaits a final decision from the National Institute for Health and Care Excellence that will look at the clinical benefits and cost-effectiveness of lecanemab and determine if it should be routinely offered by the NHS in England.
“Lecanemab is the first disease modifying treatment for Alzheimer’s disease with a market approval in the UK, and to ensure the health system is prepared for future advances in treatments, a dedicated NHS team is also looking ahead to 27 other drugs which are currently in advanced clinical trials that could be potentially approved by 2030.”
For background
- NHS England has a dedicated national team in place to plan for the roll out of a new class of disease modifying treatments for Alzheimer’s disease – they first need to be approved by the MHRA and NICE which have to assess the safety and clinical and cost effectiveness of the treatment
- If anyone is concerned about having signs and symptoms of Alzheimer’s disease, they should speak to their GP
- There’s currently no cure for Alzheimer’s disease, but medicines are available that can help relieve some of the symptoms
- There are also things people can do to reduce their risk or delay the onset of dementia, such as stopping smoking, cutting down on alcohol, eating a healthy, balanced diet and staying physically fit and mentally active.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![](https://www.einnews.com/tracking/article.gif?aid=737760405§ion=england.nhs.uk&a=rcO6cs7104Ab6NUf&i=PavHPZlb76Rn581J)